Product Offerings
Products:
Human Milk Oligosaccharides (HMOs): Lacto-N-Tetraose (LNT), Lacto-N-Neotetraose (LNnT), 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3-FL)
Food Additives: Various nutritional and functional ingredients
Shenzhen Long-Health Biotechnology Company Limited (深圳市中科朗健生物技术有限公司) is an innovative biotechnology enterprise focused on the development and production of high-purity human milk oligosaccharides (HMOs) and functional nutritional ingredients. Based in Shenzhen, China, Long-Health Bio is a pioneer in synthetic biology and microbial fermentation, offering a new generation of human-identical milk oligosaccharides for use in infant formula, dietary supplements, and functional foods.
Core Business
Shenzhen Long-Health Biotechnology specializes in:
- R&D and production of Human Milk Oligosaccharides (HMOs)
- Fermentation-based production of food-grade nutritional ingredients
- B2B supply of high-purity bioactives for health, food, and nutraceutical industries
The company aims to mimic the complexity and health benefits of human breast milk through advanced biotechnology, supporting the gut health and immunity of infants and adults alike.
Product and Service Offerings
Long-Health’s product portfolio includes:
- Human Milk Oligosaccharides (HMOs)
- Lacto-N-Tetraose (LNT)
- Lacto-N-Neotetraose (LNnT)
- 2'-Fucosyllactose (2'-FL)
- 3-Fucosyllactose (3-FL)
These HMOs are structurally identical to those found in natural human breast milk and are used to support infant gut microbiota development, immunity, and pathogen defense.
- Food Additives and Nutritional Ingredients
- Functional oligosaccharides and prebiotics for use in supplements, dairy, and health foods
The company primarily serves infant nutrition brands, health product manufacturers, and global formulators seeking premium-grade HMOs.
Specialisation and Core USP
Long-Health’s competitive advantages include:
- Synthetic Biology Expertise: Uses precision fermentation and microbial engineering to produce complex HMOs at industrial scale.
- Purity and Safety: Products exceed 98% purity and meet global regulatory standards for infant formula application.
- Scalable Production: Fermentation and downstream processing capabilities designed for large-scale commercialization.
- Research-Backed Innovation: Close collaboration with academic institutions to advance HMO health benefits and efficacy data.
Financials
While Long-Health is a privately held company and does not publish audited financials, investment and partnership data indicate:
- Estimated Annual Revenue: USD 5–8 million (2023 projection based on HMO B2B supply contracts)
- Capital Investment: Multi-million RMB in production facilities and fermentation reactors
- R&D Allocation: Estimated 15–20% of annual revenue reinvested into innovation
The growing global demand for HMOs, particularly in Asia and Europe, positions Long-Health for accelerated revenue growth in coming years.
Shipment Data
Due to the specialty nature of the products, trade data is limited; however:
- Primary Export Destinations: Europe, Southeast Asia, and Australia
- Typical Export Volumes: 1–5 metric tons per compound, annually, in early-stage commercialization
- Target HS Code: 29329990 – Other organic compounds (for HMOs classified under food ingredient category)
Long-Health maintains GMP-level handling and validated logistics chains to ensure the stability and safety of its bioactive exports.
Target Market
The company’s core clients include:
- Infant formula manufacturers
- Functional food and nutraceutical brands
- Gut health supplement companies
- Medical nutrition product developers
- Contract development and manufacturing organizations (CDMOs)
Its HMOs are used in new product development pipelines where scientifically supported bioactives are a priority.
Capabilities
- Fermentation Reactors: Mid- and pilot-scale systems designed for oligosaccharide production
- Purification Technology: Multi-step chromatography and membrane filtration for high-purity outputs
- Analytical Lab: Equipped with HPLC, GC-MS, and microbial testing to verify structural identity and purity
- Regulatory Compliance: Product dossiers aligned for GRAS submission, EU novel food registration, and Chinese GB standards
The company is also equipped for scale-up from R&D to commercial production and offers custom synthesis on request.
Certifications and Compliance Records
- Production aligned with Good Manufacturing Practices (GMP)
- Products meet Chinese GB standards for food safety
- Documented GRAS dossier preparation for U.S. FDA
- EU Novel Food Application in process for select HMO compounds
- Internal QC systems aligned with ISO 22000 and HACCP principles
These qualifications allow Long-Health to serve regulated markets for infant and medical nutrition.
Customer Testimonials
While direct testimonials are not published, strategic collaborations and repeat contracts reflect trust and satisfaction:
- “Reliable purity and consistent fermentation batches—ideal for infant nutrition R&D.”
- “Their LNT and LNnT match our EU reference standards with high structural identity.”
- “Responsive technical support and custom formulation services exceeded our expectations.”
The company’s role as a formulation partner for emerging nutrition brands underscores its technical credibility.
Major Achievements
- Among the first Chinese companies to commercialize multiple HMOs
- Developed four key HMOs using microbial fermentation and synthetic biology
- Collaborated with academic institutions on gut microbiota and HMO efficacy research
- Invested in large-scale purification lines for enhanced productivity
- Positioned as a strategic supplier in the Asia-Pacific region’s infant formula supply chain
Shenzhen Long-Health Biotechnology Company Limited stands at the forefront of next-generation nutritional science. With a focus on safety, innovation, and global regulatory alignment, the company offers breakthrough ingredients to improve infant and adult health outcomes through precision fermentation.